When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ADMS - Adamas Pharma's Gocovri shows long-term treatment effect in late-stage Parkinson's study
Adamas Pharmaceuticals Inc.
Final results from a two-year open-label Phase 3 clinical trial, EASE LID 2, evaluating Adamas Pharmaceuticals' (ADMS-3.1%) GOCOVRI (amantadine) in patients with Parkinson's disease (PD) showed a sustained treatment effect. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders in Hong Kong.
More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,